Safety and efficacy of valproic acid preparations.

Background: Rising of the cost of drug therapy is one of the most notable negative tendencies of modern medicine. The main reasons for this trend are the increased costs for preclinical and clinical phases of drug development. Reproduction of drugs after cessation of patent protection is much less costly.

[Trimetazidine in pectoris patients older than 65 years with stable angina].

Aim: To study efficacy of trimetazidine including action on quality of life in patients over 65 years of age with stable angina pectoris.

Material: Seventy two patients (75% men, age 65-80 years) with stable class II-III angina not completely controlled by baseline conventional combined antianginal therapy (nitrates, beta-blockers, and calcium antagonists).

Methods: Trimetazidine (60 mg/day) was added to baseline therapy for 12 weeks.